Who is sponsoring NCT01146925?

NCT01146925 is sponsored by CorMedix.

What condition does NCT01146925 study?

NCT01146925 studies Contrast-Induced Acute Kidney Injury.

What drugs are being tested in NCT01146925?

Interventions: CRMD-001-Deferiprone, Placebo.

What is the status of NCT01146925?

NCT01146925 is currently COMPLETED.

Last reviewed 2011-06-23 · How we verify

A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury

NCT01146925 Phase 2 COMPLETED

The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.

Details

Lead sponsor	CorMedix
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2010-06
Completion	2011-06

Conditions

Contrast-Induced Acute Kidney Injury

Interventions

CRMD-001-Deferiprone
Placebo

Primary outcomes

Biomarker evidence of Acute Kidney injury — 8 Days
Mean paired change in a panel of acute kidney injury (AKI) biomarkers (urinary NGAL, LFABP, interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), urinary alpha GST (proximal tubular injury), Pi GST (distal tubular injury) and cystatin C; serum cystatin C) from baseline (Day 1) to peak in the deferiprone and placebo treatment groups, within 192 hours of contrast exposure

Countries

United States